Four-Drug combo trial aims to beat standard myeloma treatment
NCT ID NCT07334535
Summary
This study is testing whether adding a fourth drug (isatuximab) to the standard three-drug combination works better for people with high-risk multiple myeloma who cannot receive stem cell transplants. Researchers will compare the four-drug combination against the standard three-drug treatment in 117 newly diagnosed patients. The main goal is to see if the four-drug combination can eliminate more cancer cells from the bone marrow after 12 months of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Junling Zhuang
Beijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.